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OBJECTIVEdTo examine the acute and 24-h glycemic responses to reductions in postexer-
cise rapid-acting insulin dose in type 1 diabetic patients.
RESEARCH DESIGN AND METHODSdAfter preliminary testing, 11 male patients
(24 6 2 years, HbA1c 7.7 6 0.3%; 61 6 3.4 mmol/mol) attended the laboratory on three
mornings. Patients consumed a standardized breakfast (1 g carbohydrate z kg21 BM; 380 6
10 kcal) and self-administered a 25% rapid-acting insulin dose 60 min prior to performing 45
min of treadmill running at 72.5 6 0.9% VO2peak. At 60 min postexercise, patients ingested a
meal (1 g carbohydrate z kg21 BM; 6606 21 kcal) and administered a Full, 75%, or 50% rapid-
acting insulin dose. Blood glucose concentrations were measured for 3 h postmeal. Interstitial
glucose was recorded for 20 h after leaving the laboratory using a continuous glucose monitoring
system.
RESULTSdAll glycemic responses were similar across conditions up to 60 min postexercise.
After the postexercise meal, blood glucose was preserved under 50%, but declined under Full
and 75%. Thence at 3 h, blood glucose was highest under 50% (50% [10.46 1.2] vs. Full [6.26
0.7] and 75% [7.6 6 1.2 mmol z L21], P = 0.029); throughout this period, all patients were
protected against hypoglycemia under 50% (blood glucose#3.9; Full, n = 5; 75%, n = 2; 50%, n =
0). Fifty percent continued to protect patients against hypoglycemia for a further 4 h under free-
living conditions. However, late-evening and nocturnal glycemia were similar; as a consequence,
late-onset hypoglycemia was experienced under all conditions.
CONCLUSIONSdA 25% pre-exercise and 50% postexercise rapid-acting insulin dose pre-
serves glycemia and protects patients against early-onset hypoglycemia (#8 h). However, this
strategy does not protect against late-onset postexercise hypoglycemia.
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Patients with type 1 diabetes are en-couraged to engage in regular exerciseas part of a healthy lifestyle (1,2).
However, engaging in exercise is not with-
out its difﬁculties (1). Defective glucose
regulation presents a signiﬁcant challenge
in preventing hypoglycemia during, and
particularly after, exercise (3,4). Exercise-
induced hypoglycemia is both a frequent
(5) and dangerous occurrence (6) and
remains a major obstacle to patients who
wish to engage in exercise (7).
Much of the literature has focused on
providing strategies to help combat hypo-
glycemia during, and early after, exercise
(8–17), with investigations focusing on al-
tering exercise modality (14,18), carbohy-
drate consumption (12,16,17), and
reductions to pre-exercise, rapid-acting in-
sulindose (10–12,17,19). Prior tomoderate-
intensity, continuous, aerobic exercise, it is
recommended that patients should reduce
their prandial rapid-acting insulin dose by
;75% to prevent hypoglycemia during
exercise (10–12). However, despite best
preserving blood glucose, it has been
shown that this strategy is not fully protec-
tive against postexercise hypoglycemia
(11,12). This has, in part, been attributed
to iatrogenic causes (11), whereby patients
administer their usual doses of rapid-acting
insulin in a heightened insulin-sensitive
state, potentially leading to unexpected
falls in blood glucose and, consequently,
hypoglycemia (11).
A potential strategy to help minimize
the risk of developing hypoglycemia after
exercise could be to reduce the dose of
rapid-acting insulin administered with
the postexercise meal (20). Exercise in-
creases the sensitivity of the body to in-
sulin formany hours after exercise (3) and
patients could be faced with a window of
particularly high sensitivity around the
postexercise meal, whereby greater rates
of glucose uptake could occur to supple-
ment the high metabolic priority of re-
plenishing muscle glycogen (21). Thus,
the meal consumed after exercise is im-
portant. With this in mind, it would be
intuitive to reduce the amount of insulin
administered with the meal consumed at
this time; this may preserve glycemia and
prevent postexercise hypoglycemia. Con-
versely, severe reductions in rapid-acting
insulin dose may incur prolonged postex-
ercise hyperglycemia, even more so if the
pre-exercise dose is also reduced. How-
ever, there is a lack of data to conﬁrm or
refute these hypotheses. In addition, it
would be prudent to examine the extent
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to which rapid-acting insulin dose ad-
justments may help combat late falls in
glycemia after exercise, considering type
1 diabetic patients are susceptible to late-
onset, postexercise hypoglycemia (3),
suggested to be due to a biphasic response
in glucose uptake occurring early and also
late after exercise (22). Therefore, the aim
of this study was to examine the acute and
24-h postexercise glycemic responses to
reducing the postexercise rapid-acting in-
sulin dose, when using the recommended
pre-exercise insulin reductions, in type 1
diabetic patients.
RESEARCH DESIGN AND
METHODS
Patients
The study population consisted of 11
male type 1 diabetic patients (mean 6
SEM; age 24 6 2 years, BMI 22.6 6 0.6,
duration of diabetes 15 6 2 years,
HbA1c 7.7 6 0.3%, 61 6 3.4 mmol/mol,
VO2peak 536 1 mL z kg zmin
21). Patients
were eligible for inclusion if they were
between 18 and 35 years of age with a du-
ration of diabetes.2 years on enrollment.
Patients were treated with a stable basal-
bolus insulin regimen composed of either
insulin glargine (n = 8) or detemir (n = 3)
and fast-acting insulin analogs aspart
(n = 10) or lispro (n = 1) for a minimum
of 6 months. Patients were regularly and
consistently active (participating in aerobic-
based exercise for at least 30min at a time,
three times per week), free of diabetes-
related complications, including hypogly-
cemia unawareness, and receiving no
additional medication other than insulin.
This study was approved by the local Na-
tional Health Service Research Ethics
Committee. All patients who participated
provided written informed consent. Pa-
tients attended a preliminary screening
visit, in which a comprehensive medical
history and physical examination was-
conducted. Additionally, patients com-
pleted a cardiopulmonary exercise stress
test to assess cardiac function in response
to exercise. All screening procedures
complied with American College of
Sports Medicine (ACSM) Guidelines for
Exercise Testing and Prescription (23).
Eligible patients underwent randomiza-
tion by a computer program to determine
the sequence of three crossover arms.
After the preliminary prescreening,
patients attended four laboratory ses-
sions. On visit 1, peak cardiorespiratory
parameters were collected during the
completion of an incremental-maximal
treadmill run protocol (11,12). The tread-
mill run started at a velocity of 8 km z h21
and increased 1 km z h21 every 3 min to
volitional exhaustion, as per West et al.
(11,12). During this visit, anthropometric
variables were also collected (body mass,
stature, and BMI). Visits 2, 3, and 4 were
experimental trials.
Prelaboratory phase
Patients were ﬁtted with a continuous
glucose monitoring system (CGMS; iPro2,
Medtronic Diabetes, Northridge, CA) a
minimum of 24 h before attending the
laboratory and replicated their diet and
activity patterns for 24 h prior tomain trials.
CGMS
The iPro2 (Medtronic Diabetes, North-
ridge, CA) system consists of a needle-like
sensor that is inserted into subcutaneous
tissue. Sensor readings are obtained and
stored in the memory of the monitor,
which is attached to the indwelling sen-
sor. Patients wore Enlite sensors (Med-
tronic Minimed, Northridge, CA), which
were placed in the postural-lateral ab-
dominal region to minimize the physio-
logical time lags between blood and
interstitial glucose (24). The sensor was
inserted 24 h prior to each main trial,
with the site of insertion replicated be-
tween trials. Sensors were removed 24 h
after leaving the laboratory. During sen-
sor wear, patients self-recorded capillary
blood glucose concentrations at least four
times per day for calibration purposes
using a testing meter (GlucoMen LX; Me-
narini Diagnostics, Berkshire, U.K.). Sen-
sor data were retrospectively processed
using CareLink iPro software (Medtronic
Diabetes) and iPro2 Retrospective Algo-
rithm (Medtronic Diabetes) calibration
routines.
Diet and activity replication
Patients arrived at the laboratory after an
overnight fast, having replicated their diet
in the previous 24 h (assessed using
weighed dietary recording sheets). Addi-
tionally, patients were instructed to main-
tain their normal insulin regimen, with
basal insulin dose standardized (dose, in-
jection site, and time of injection) across
trials. Patients were given a pedometer
(Omron Healthcare Europe B.V., Hoofd-
dorp, the Netherlands), which they were
instructed to wear in the previous 24 h.
Patients were required to avoid strenuous
activity in the previous 48 h and maintain
similar activity patterns between trials.
Testing procedure
All main trials were conducted on a morn-
ing (;08:00 A.M.), with a minimum of 7
days between trials; patients replicated their
trial start time across conditions. After ar-
rival to the laboratory, patients were seated
while a 20-gauge cannula (Vasoﬁx; B. Braun
Melsungen AG, Melsungen, Germany) was
inserted into the antecubital vein of their
nondominant arm. A 6-mL resting venous
blood sample was taken, of which 20 mL
was used for the immediate quantiﬁcation
of glucose and lactate (Biosen C-Line; EKF
Diagnostic GmbH, London, U.K.) and 10
mL was analyzed for hemoglobin and he-
matocrit (Hemo Control; EKF Diagnostic
GmbH), which was used to correct for
changes in plasma volume (25). Venous
blood (5 mL) was collected in a serum sep-
aration tube thatwas centrifuged for 15min
at 3,000 rev z min21 and stored at 2808C
for later analysis of rapid-acting insulin (In-
vitron Insulin Assay; Invitron, Monmouth
U.K.) and b-hydroxybutyrate (Ranbut;
Randox Laboratories, London, U.K.).
Rapid-acting insulin was measured in pa-
tients using basal insulin glargine only. Im-
mediately after this sample, patients
administered a 25% (1.8 6 0.1 IU) dose
(i.e., a 75% reduction) of rapid-acting insu-
lin into the abdomen, as recommended by
Rabasa-Lhoret et al. (10) and West et al.
(11). All patients were familiar with carbo-
hydrate counting and were administering
1.0 6 0.1 IU of rapid-acting insulin per
10 g of carbohydrate. The injection site
was standardized across trials through ad-
ministration at half the distance between
the anterior-superior iliac crest and the na-
val. Insulin aspart and lispro were adminis-
tered using Novopen3 (NovoNordisk,
Bagsvaerd, Denmark) and HumaPen
LUXURA (Eli Lilly, London, U.K.), respec-
tively. After administration of the reduced
rapid-acting insulin dose, patients con-
sumeda cereal-basedbreakfastmeal (frosted
ﬂakes, semiskimmed milk, and peaches)
equating to 1 g carbohydrate z kg21 BM
(3806 10 kcal) within a 5-min period.
After consuming breakfast, patients
remained rested, with blood samples
collected at 30 and 60 min after the
ingestion of the meal. Sixty minutes after
breakfast, patients performed 45 min of
steady-state treadmill (Woodway, Weil
am Rhein, Germany) running at 72.5 6
0.9% VO2peak, an intensity that falls
within the recommendations of ACSM
(23) for exercising individuals with diabe-
tes. Breath-by-breath respiratory parame-
ters (MetaLyzer 3B; Cortex, Leipzig,
Germany) and heart rate (S810; Polar,
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Kempele, Finland) were continuously re-
corded throughout exercise. After the ces-
sation of exercise, blood samples were
collected at 0, 5, 15, 30, and 60 min post-
exercise. At 60 min postexercise, in a ran-
domized and counter-balanced fashion,
patients administered a Full (7.5 6 0.3
IU), 75% (5.6 6 0.2 IU), or 50% (3.7 6
0.1 IU) rapid-acting insulin dose, which
was injected into the contralateral ab-
dominal site to the pre-exercise, rapid-
acting insulin dose. Patients then
consumed a pasta-based lunch meal
(pasta, tomato-based sauce, cheddar
cheese), equating to 1 g carbohydrate z
kg21 BM (660 6 21 kcal), and then re-
mained at rest for 180 min postmeal.
Blood samples were collected every 30
min throughout the postmeal period;
patients could drink water ad libitum.
Hypoglycemia was deﬁned as a blood
or interstitial glucose concentrations
of #3.9 mmol z L21 (15). If patients
experienced hypoglycemia during the
laboratory period, a 20-g carbohy-
drate bolus was administered (Lucozade;
GlaxoSmithKline, Middlesex, U.K.).
Postlaboratory period
During CGMS wear, patients were re-
quired to replicate their diet across trials
through the use of a weighed food diary.
Dietary intake and insulin administration
was self-recorded, with patients required
to indicate if additional carbohydrate in-
take had been ingested to correct falling
blood glucose. Patients were required to
keep meal times and rapid-acting insulin
dose consistent across trials. Patients con-
tinued to record a minimum of four
capillary blood glucose concentrations
daily for CGMS calibration.
Data analysis
Statistical analysis was performed us-
ing PASW statistics software (IBM
PASW version 18; IBM, Armonk, NY).
A repeated-measures ANOVA on three
levels (condition 3 time) was conducted,
with Bonferroni-corrected pairwise com-
parisons and paired samples Student t test
used to examine time and treatment effects,
respectively. Statistical signiﬁcance was ac-
cepted at P # 0.05. Area under the curve
was calculated using the methods de-
scribed by Wolever and Jenkins (26).
RESULTS
Prelaboratory phase
Patients displayed similar glycemic con-
trol during the 24 h before arriving to the
laboratory, with similar mean (Full, 8.66
0.4; 75%, 7.7 6 0.5; 50%, 8.1 6 0.6
mmol z L21; P = 0.451) and total intersti-
tial glucose area under the curve (Full,
12,389 6 705; 75%, 10,986 6 765;
50%, 11,385 6 791 mmol z L21 z min21;
P = 0.400) across trials. During this time,
dietary patterns were similar, with no dif-
ferences in total energy intake (Full,
2,249 6 110; 5%, 2,290 6 178; 50%,
2,1306128kcal;P =0.750),with percent-
age contribution from carbohydrate (Full,
526 3; 75%, 496 4; 50%, 496 4%; P =
0.844), fat (Full, 29 6 3; 75%, 30 6 3;
50%, 33 6 3%; P = 0.958), and protein
(Full, 18 6 2; 75%, 21 6 3; 50%, 18 6
2%; P = 0.843) similar between conditions.
No differences were observed in activity
patterns with similar total steps recorded
across conditions (Full, 7,507 6 124;
75%, 8,028 6 119; 50%, 8,056 6 138
steps; P = 0.627).
Laboratory phase
The absolute blood glucose responses are
presented in Fig. 1. There was a signiﬁ-
cant time effect (P , 0.001, partial-h2 =
0.643) and a signiﬁcant condition3 time
interaction for absolute blood glucose
concentrations (P , 0.001, partial-h2 =
0.290). Fasting blood glucose concentra-
tions were similar between conditions
(Full, 7.2 6 0.9; 75%, 7.1 6 0.7; 50%,
7.1 6 0.6 mmol z L21; P = 0.594). After
the ingestion of the breakfast meal and
reduced rapid-acting insulin dose, blood
glucose peaked at 60 min and was similar
across conditions (Fig. 1). Serum insulin
and b-hydroxybutyrate responses are
presented in Table 1. There were no dif-
ferences in fasting serum insulin (P =
0.989) or b-hydroxybutyrate (P =
0.962) concentrations across conditions
(Table 1). Pre-exercise serum insulin
and b-hydroxybutyrate responses were
similar across conditions (P . 0.05)
(Table 1).
There were no differences in exercis-
ing rates of % VO2peak (Full, 73.86 0.01;
75%, 72.8 6 0.01; 50%, 70.8 6 0.01%;
P = 0.575) or peak heart rate (Full, 806 2;
75%, 796 3; 50%, 796 1%; P = 0.631).
The decline in blood glucose with exer-
cise was similar across conditions (Full,
D =26.86 0.03; 75%, D =26.96 0.03;
50%, D = 26.2 6 0.03 mmol z L21; P =
0.891); moreover, patients elicited simi-
lar peak lactates immediately postexer-
cise (Full, 3.7 6 0.6; 75%, 3.8 6 0.5;
50%, 3.7 6 0.5 mmol z L21; P = 0.965).
There were no incidences of hypoglyce-
mia during exercise, with all patients
completing the exercise protocol on
each occasion.
Postexercise intervention
After the postexercise meal and rapid-
acting insulin dose, total serum insulin
area under the curve was signiﬁcantly
lower under 50% (21,7486 4,799 pmol z
L21 z min21) when compared with Full
(38,1666 6,716 pmol z L21 z min21, P =
0.004) and 75% (33,351 6 5,634 pmol z
L21 z min21, P = 0.031). Individual peak
serum insulin concentrations were lowest
under 50% (836 29 pmol z L21 zmin21)
compared with 75% (196 6 42 pmol z
L21 z min21, P = 0.017) and Full (229 6
44 pmol z L21 zmin21, P = 0.020). Blood
glucose concentrations decreased under
Full and 75%; however, under 50%,
blood glucose was preserved, eliciting
similar concentrations to premeal (Fig.
1). During this time, ﬁve patients experi-
enced hypoglycemia under Full and two
under 75%, whereas under 50%, all pa-
tients were protected. Furthermore,
some participants experienced multiple
bouts of hypoglycemia, with total epi-
sodes across each trial greatest under
Full (Full, n = 9; 75%, n = 6; 50%, n =
0). On average, blood glucose concentra-
tions were 2.8 6 0.2 mmol z L21 before
receiving carbohydrate supplementation.
Upon leaving the laboratory on 180 min
postmeal, blood glucose concentrations
were greater under 50% when compared
with Full and 75% (Fig. 1). There were
no conditional differences in blood lac-
tate responses (P = 0.996) or serum
b-hydroxybutyrate (P = 0.076) (Table 1).
Postlaboratory phase
The interstitial glucose responses are pre-
sented in Fig. 2. After leaving the labora-
tory, 50% prevented hypoglycemia for a
further 4 h, meaning the ﬁrst hypoglyce-
mic episode under 50% occurred at 8 h
postexercise. During the evening (Fig. 2),
total interstitial glucose area under the
curve was signiﬁcantly greater under
50% (2,709 6 245 mmol z L21 z min21)
when compared with Full (1,706 6 247
mmol z L21 zmin21, P, 0.001) and 75%
(1,860 6 244 mmol z L21 z min21, P ,
0.001).
By 9 h postexercise, glycemia under
50% had decreased over time, with con-
centrations lower than those elicited
upon leaving the laboratory (Fig. 2). After
9 h, interstitial glucose concentrations
became comparable across conditions
and were lowest during the night (Fig.
2). Nighttime and morning glycemic
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responses were also similar across trials
(Fig. 2).
All patients experiencing hypoglyce-
mia during the laboratory period also
experienced further hypoglycemic epi-
sodes during sleep. The total number of
hypoglycemic episodes during the post-
laboratory phase was lowest under 50%
(Table 2). Of the total hypoglycemic epi-
sodes across all trials, 82% occurred noc-
turnally (Table 2). Additionally, the
number of patients who self-corrected
blood glucose to prevent further declines
in glycemia was less under 50% (n = 2)
when comparedwith 75% (n = 6) and Full
(n = 6).
During the postlaboratory period,
total energy consumed (Full, 1,588 6
234; 75%, 1,769 6 275; 50%, 1,731 6
141 kcal; P = 0.836), with contribution
from carbohydrate (Full, 55 6 4; 75%,
47 6 5; 50%, 48 6 4%; P = 0.516), fat
(Full, 30 6 4; 75%, 31 6 4; 50%, 34 6
4%; P = 0.916), and protein (Full, 16 6
2; 75%, 22 6 6; 50%, 18 6 2%; P =
0.827), was similar between conditions.
Moreover, there were no differences in
the total amount of insulin administered
or in the insulin to carbohydrate ratio (P
. 0.05). No differences were observed in
activity patterns during the 24-h postex-
ercise period, with similar steps recorded
(Full, 5,341 6 95; 75%, 4,786 6 87;
50%, 5,543 6 108 steps; P = 0.877)
across conditions.
CONCLUSIONSdThe aim of this
study was to examine the acute and 24-h
glycemic responses to reductions in post-
exercise rapid-acting insulin dose, when
the recommended pre-exercise insulin
reductions were used, in patients with
type 1 diabetes. The results demonstrate
that despite a large reduction in the pre-
exercise, rapid-acting insulin dose, it is
important that the postexercise dose is
also heavily reduced. We have demon-
strated that a reduction in postexercise
rapid-acting insulin of 50% best preserves
glycemia and provides the greatest pro-
tection against hypoglycemia early after
exercise (;8 h). However, beyond this
time, this strategy becomes less effective.
A potential mechanism explaining the
late fall in glycemia could be the adminis-
tration of further unchanged doses of
rapid-acting insulin and/or unchanged
circulating basal insulin concentrations
during a second period of elevated glucose
uptake (22).
All patients completed a bout of
moderate-intensity aerobic exercise
(;73% VO2peak), running at a velocity
of 9.3 6 0.3 km z h21 and expending
708 6 16 kcal, with no incidences of hy-
poglycemia during exercise. This comple-
ments the recommendations of prior
literature (10–12) and emphasizes the im-
portance of reducing the rapid-acting
insulin dose before exercise. Furthermore,
patients were, on average, within euglyce-
mic ranges for 60 min after exercise,
Figure 1dTime-course changes in blood glucose from rest. Data presented as mean 6 SEM. Triangles, Full; squares, 75%; diamonds, 50%.
Transparent sample point within a condition indicates signiﬁcant difference from premeal concentrations (P# 0.05). *Signiﬁcantly different from
Full (P# 0.05); **signiﬁcantly different from Full and 75% (P# 0.05). Thatched area indicates exercise, and vertical dashed line break indicates
postexercise intervention. Note that test meal and insulin were administered immediately after rest and 60-min postexercise sample points.
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suggesting this strategy exposes patients to
only transient periods of hyperglycemia
prior to exercise (Fig. 1).
After the consumption of the post-
exercise meal, blood glucose was best
preserved with a 50% reduced rapid-
acting insulin dose, which protected all
patients from hypoglycemia throughout
the postexercise meal period, whereas
blood glucose concentrations declined
under both Full and 75% doses (Fig. 1).
The exact mechanisms underpinning
these ﬁndings are not entirely known.
Moderate-intensity running exercise
requires a contribution from muscle gly-
cogen (27,28), of which the replenish-
ment is of a high metabolic priority (21),
with muscle glycogen depletion sugges-
ted to have a role in the development of
postexercise hypoglycemia (29). After ex-
ercise, glycogen synthesis is increased
dramatically, thought to be driven pri-
marily by depleted glycogen (30,31), an
upregulation of insulin signaling path-
ways (32), and a prolonged increase in
the permeability of the muscle cell mem-
brane to glucose (33). Taken together, an
increased rate of glucose transport into
the muscle and an increased capacity to
convert glucose to glycogen results in a
window where there is likely an increased
potency of the administered rapid-acting
insulin (34).
To suggest that the glycemic respon-
ses of our patients under Full and 75% are
solely due to depleted muscle glycogen
stores is difﬁcult, as large carbohydrate
boluses (1.0 g carbohydrate z kg21 BM)
were ingested before and after exercise,
which would have helped supplement
glycogen reserves (21). However, addi-
tional explanations for why hypoglycemia
was experienced during the Full and 75%
conditionsmay be that the administration
of larger doses of rapid-acting insulin
created a milieu of relative hyperinsuline-
mia, in turn suppressing hepatic glucose
production and enhancing glucose up-
take (34), potentially into nonexercised
tissue (27). Irrespective of the mecha-
nisms at play, we have demonstrated the
importance of reducing the dose of rapid-
acting insulin administered with the meal
after exercise. In contrast to current rec-
ommendations that advocate a reduction
of 30% (35), we found a 50% reduction
was necessary to prevent falls in blood
glucose early after exercise. Although se-
rum b-hydroxybutyrate throughout the
postmeal period was, on average, greatest
under 50% (Table 1), these concentra-
tions were of little clinical signiﬁcance,
with concentrations well below those
deemed hyperketonemic (.1.0 mmol21)
(36). From a clinical viewpoint, a 50%
reduction in rapid-acting insulin after ex-
ercise, when the pre-exercise dose was
also heavily reduced, does not increase
ketone body concentrations.
Interstitial glucose concentrations
revealed a preservation of glycemia under
50% for a further 4 h after leaving the
laboratory, meaning patients had been
protected against hypoglycemia for 8 h
postexercise. However, patients were ex-
posed to hyperglycemia during this time.
In comparison, glycemia during the even-
ing (between 4 and 9 h postexercise) (Fig.
2) was signiﬁcantly lower under both Full
and 75% conditions, with patients expe-
riencing further hypoglycemic episodes
under these conditions. However, at ;7 h
postexercise, there was a decline in in-
terstitial glucose concentrations under
50%, such that at ;9 h postexercise, gly-
cemia was similar between conditions.
The decline in interstitial glucose was
consistent across trials (Fig. 2) and was
coincidental with evening meal time. Pa-
tients replicated dietary habits (i.e., meal
composition, time of consumption, and
rapid-acting insulin dose), and their basal
insulin regimen was standardized across
trials. Type 1 diabetic patients face partic-
ular difﬁculty in avoiding hypoglycemia
7–11 h postexercise, as the requirement
for glucose to maintain euglycemia is in-
creased (26,37). Considering that in-
creased insulin sensitivity may persist for
.48 h after exercise, an additional strategy
could be to reduce the basal insulin dose.
However, this strategy requires planning
exercise in advance and offers little ﬂexi-
bility regarding the timing of exercise; if
unforeseen circumstances prevent plan-
ned exercise from taking place, the patient
is likely to be exposed to prolonged peri-
ods of hyperglycemia (38). Therefore, it
may be more appropriate to further adjust
the rapid-acting insulin dose during this
time.
Of the total number of hypoglycemic
episodes experienced across all trials dur-
ing the postlaboratory period, 82% oc-
curred nocturnally. Therefore, sleep may
be a contributing factor to the increased
incidence of hypoglycemia during the
night (3). As well as recent exercise (5,
20), antecedent hypoglycemia (6) may
blunt symptomatic and autonomic re-
sponses to hypoglycemia later in the
day, particularly during sleep (39). This
is important, as those patients who expe-
rienced hypoglycemia in the laboratory
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eliciting blood glucose concentrations
,3 mmol z L21 also experienced hypogly-
cemia again during sleep. These data
suggest that if patients experience hypo-
glycemia early after exercise, there is po-
tential that they are at an increased risk of
blood glucose falling again during the
night. Although only 18% of patients
experienced nocturnal hypoglycemia
under 50%, the late fall in glycemia
means the risk, albeit less, may still be
present for patients despite the large
reductions in pre- and postexercise
rapid-acting insulin dose. Experiencing
hypoglycemia during sleep is a real fear
for type 1 diabetic patients (39), which is
likely to be exacerbated when exercise is
performed during the day. Therefore,
there is a need to further reﬁne current
exercise recommendations for type 1 di-
abetic patients such that patients can en-
gage in regular exercise with a reduced
risk, and fear, of postexercise nocturnal
hypoglycemia.
Sport and recreational activities vary
greatly in terms of their physiological
demands and metabolic responses. The
effects of changing the intensity, duration,
or mode of exercise may therefore neces-
sitate manipulating the rapid-acting in-
sulin dose accordingly to account for
these changes. Moreover, the feeding
pattern used in this study (60 min before
and after exercise) may not be typical of
the normal dietary habits of exercising
patients. Worthy of note, the patients
examined in this study were in good
glycemic control (HbA1c 7.7 6 0.3%,
616 3.4mmol/mol) and had a good level
of aerobic ﬁtness (VO2peak 536 1 mL z kg
z min21). Thus, there is potential that the
Figure 2dTime-course changes in interstitial glucose throughout the postlaboratory period. Data presented as mean (SEM error bars have been
removed for reader clarity). Black line, Full; blue line, 75%; red line, 50%. **Interstitial glucose area under the curve is signiﬁcantly different from
Full and 75% (P # 0.05). Vertical dashed line breaks indicate evening, nocturnal, or morning periods.
Table 2dThe total number of patients experiencing hypoglycemia and the total number
of hypoglycemic episodes during the postlaboratory period
Full 75% 50%
Evening No. of patients 2 1 1
Total episodes 2 1 1
Nocturnal No. of patients 4 5 2
Total episodes 7 8 4
Morning No. of patients 0 0 0
Total episodes 0 0 0
Total No. of patients 6 6 3
Total episodes 9 9 5
Hypoglycemia was deﬁned as an interstitial glucose concentration ,3.9 mmol z L21.
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glycemic response to pre- and postexer-
cise rapid-acting insulin reductions may
differ with patient age, ﬁtness, and glyce-
mic control. Although it was not possible
to address these issues within this study,
this should not detract from the clinical
application of our ﬁndings. To our
knowledge, we are the ﬁrst to investigate
postexercise rapid-acting insulin dose re-
ductions after running exercise in patients
with type 1 diabetes, when using the rec-
ommended pre-exercise insulin dose re-
ductions. We have demonstrated the
importance of large reductions in the
pre- and postexercise rapid-acting insulin
dose in preserving glycemia early after ex-
ercise and, through investigation under
free-living conditions, further highlight
that the difﬁculties related to delayed
and, in particular, nocturnal postexercise
hypoglycemia are still existent despite the
application of large rapid-acting insulin
dose reductions before and after exercise.
Therefore, future research should further
investigate strategies to normalize glyce-
mia in the late postexercise period, pre-
venting late-onset hypoglycemia.
In summary, the results of the current
study suggest that a 50% reduction in
postexercise rapid-acting insulin dose,
when combined with a large pre-exercise
rapid-acting insulin reduction, preserves
glycemia and prevents hypoglycemia for
;8 h after exercise. However, patients
should be made aware that they may be
exposed to periods of hyperglycemia, but
not hyperketonemia, after the postexer-
cise meal, and there is still a risk of devel-
oping late-onset hypoglycemia. Patients
are therefore recommended to reﬁne
these strategies according to their own in-
dividual exercise routine and glycemic
responses.
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